Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. - Wikidata - awgldk - TriplyDB

Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.

Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.

http://www.wikidata.org/entity/Q36896203

about

Tremelimumab: research and clinical development Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy Immune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice.Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis.Toll-like receptor agonists: a patent review (2011 - 2013).Checkpoint inhibitors in immunotherapy of ovarian cancer.Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?Therapeutic targeting of Toll-like receptors in cutaneous disorders.Tremelimumab-Induced Graves Hyperthyroidism.Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges T cell exhaustion: from pathophysiological basics to tumor immunotherapy.Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural context.Immuno-oncology combinations: raising the tail of the survival curve.Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial.Trial Watch: Toll-like receptor agonists for cancer therapy.New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody

P2860

Q26752822-F0BAF093-626A-4C75-BA92-C3AEFE795147 Q26779221-49AFA17F-5C91-41EE-8AD6-5D23ECC71338 Q26825644-964CE22B-1478-4407-BCAB-BC2997EF272E Q26996518-9FA7054B-5A77-4DEC-82AD-6B92F6380D02 Q27335400-A5ACE2B7-B33F-4934-ABDD-77870B02029A Q28972540-41B9864F-C42E-4079-A180-9E454F40E9C9 Q36192538-03D4B3EC-8E1F-41A8-AFA6-A05BDC465526 Q36854062-2CC721A3-4432-4A9C-BEE2-BA98C2A353C4 Q37652790-AFB5DEDE-3C72-4957-BCEE-7EE04B0FEF84 Q37687530-7A14734F-696A-48CF-9D2C-84F52097962C Q37697084-DB6DC245-7F3D-4F15-9A39-C3FFBF09C36E Q38181176-E9744A7F-B56E-4B44-9209-70DD37FB8D84 Q38269568-88B88578-1FAA-42DF-9DA1-E76F3E273AF6 Q38447992-91017E67-410D-4AA2-ABAD-1686F9D4B28C Q38550117-104CFB60-911C-459A-92C8-7404D0EC8589 Q38635780-0051E006-B261-4AAB-B2DF-343762490B99 Q38806038-C8623CC8-34A2-4FBB-89FF-865AE94FF336 Q38878906-D779CC59-900E-4B75-8038-4CBAA486763F Q39078341-307D2A42-1A5B-4D85-855C-1D24BF160D05 Q42359630-7274D466-01F7-4302-8DA4-7EA80CED3D07 Q42421273-CE612897-6302-4C25-8ABF-C1548C587CDA Q42664108-761AC27B-4348-4428-BD73-B4B741140B89 Q42969291-C9B43A73-EEF9-431A-AF9E-9CB879B9FE89 Q46047154-5A56F9FC-1DA9-4CC1-8057-2FF553CC6BD1 Q56896949-215BE284-B958-4FDE-BF2D-02BFDE6D99B5

P2860

Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.

http://www.wikidata.org/entity/Q36896203

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Phase I study of tremelimumab ...... oma or advanced solid tumours.

@en

type

label

Phase I study of tremelimumab ...... oma or advanced solid tumours.

@en

prefLabel

Phase I study of tremelimumab ...... oma or advanced solid tumours.

@en

P1433

Q36896203-A44A68EF-CE85-4C22-A3CA-5EFE56A7126F

P1476

Q36896203-30211241-575E-479A-B3B1-C55018DEAC75

P2093

Q36896203-19FAC619-C227-4E0D-9919-7A401ADD5EFE

Q36896203-64064E60-BCF7-432B-B8D6-C918A9312FBE

Q36896203-6B2B930E-1ED9-42A7-8DEB-3B7135459F63

Q36896203-7BC5A291-2496-4807-B217-E23B92E4EE05

Q36896203-9580C900-12BB-454C-8D66-EC589BB814A4

Q36896203-A303F339-81EA-4436-9CE2-BD2F0F6DA979

Q36896203-A657415F-11E0-4FCC-A458-C55F8BB80D0C

Q36896203-C07A7559-B9CB-4448-83DF-16DB2EE6786F

Q36896203-F67736C3-5E77-480C-95A2-9545E6C04054

P2860

Q36896203-1A8E2E10-E99B-4309-AE26-22AA874E34C7

Q36896203-244C83E8-4570-416A-8EF0-A1E2FBEBFE8F

Q36896203-462B0581-8DF2-409D-AD28-9BED20E7AB47

Q36896203-46BDEFE5-EA5A-40FD-A85A-F644881285DC

Q36896203-4EC1474E-A381-4A21-869A-E4C793B20882

Q36896203-6A092998-10F3-43C8-8368-4ABF15A15BD3

Q36896203-7C148F39-B69A-4D45-BD36-C4ECD713B65D

Q36896203-802E6078-9E54-49AE-AFBC-59D7AE9921E7

Q36896203-91582BCD-E555-4635-A1C6-759B6ECD764E

Q36896203-9E0A6DFC-BD2A-4102-8AEE-856D9C450003

P2888

Q36896203-E3906C91-0A0E-4F5F-A86F-19AEB9D2AC17

P304

Q36896203-11193ED6-A974-4352-ADAA-C3C4C413CCEA

P31

Q36896203-675F2BE7-E4D6-4C01-9E67-04BF4A4B6283

P356

Q36896203-E39DE7B6-B986-473F-A794-4DA87817718F

P407

Q36896203-6545AB51-5A17-41C5-A22E-AF3C477D9FFB

P433

Q36896203-C83DE32A-8EA2-4B8D-9B07-3D457FDD81DC

P478

Q36896203-B0C0F1A8-5E77-4EF0-899A-ECEB46CF3311

P577

Q36896203-26468E13-F8E3-4D4A-9C30-747F7C43FF0B

P5875

Q36896203-E5FF5FF5-2F07-4A61-B06D-5F4DC5721FB1

P6179

Q36896203-58E372A5-2705-4386-8237-EB41B5765A96

P698

Q36896203-1ACC55F7-B702-4488-B9E7-A5D293D15038

P932

Q36896203-EED697BF-033B-4266-8A99-A39A290A3B42

P356

P1433

British Journal of Cancer

P1476

Phase I study of tremelimumab ...... oma or advanced solid tumours.

@en

P2093

B Huang

http://www.w3.org/2001/XMLSchema#string

C B Mather

http://www.w3.org/2001/XMLSchema#string

C Underhill

http://www.w3.org/2001/XMLSchema#string

J Gomez-Navarro

http://www.w3.org/2001/XMLSchema#string

J McBurnie

http://www.w3.org/2001/XMLSchema#string

M A Marshall

http://www.w3.org/2001/XMLSchema#string

M Millward

http://www.w3.org/2001/XMLSchema#string

S J Meech

http://www.w3.org/2001/XMLSchema#string

S Lobb

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

CD28 and CTLA-4 coreceptor expression and signal transduction

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer.

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.

The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology.

Development of TLR9 agonists for cancer therapy

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer.

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.

P2888

P304

1998-2004

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2013.227

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236653598

http://www.w3.org/2001/XMLSchema#string

P6179

1044288366

http://www.w3.org/2001/XMLSchema#string

P698

23652314

http://www.w3.org/2001/XMLSchema#string

P932

3670507

http://www.w3.org/2001/XMLSchema#string